Holiday Notice: Expect delayed shipping. Orders ship 4/6.
FOR RESEARCH PURPOSES ONLY. NOT FOR HUMAN CONSUMPTION.

Tesamorelin — Published Research

Reviewed by: Dr. James Porter, PhD| Last updated: March 8, 2026|For laboratory reference only

← Back to Tesamorelin product page

Research Library

Published research on tesamorelin — for educational purposes only

Tesamorelin Structure and GHRH Receptor Agonism

Tesamorelin retains the full 44-amino-acid sequence of human GHRH(1-44) with a trans-3-hexenoic acid (C6) moiety conjugated to the N-terminal tyrosine via an amide bond. This modification protects the Tyr¹-Ala² bond from DPP-IV cleavage (the primary inactivation pathway for native GHRH) while preserving binding to the GHRH receptor. Receptor binding studies show similar affinity (Kd ~0.3 nM) and maximal cAMP response compared to native GHRH. The modification extends the functional half-life without preventing renal clearance. Research compound — not for human use.

Boulanger L et al. “Pharmacological and structural characterization of growth hormone-releasing factor analogs.” Peptides. 2005. PubMed

GHRH Receptor Signal Transduction

The GHRH receptor (GHRHR) is a class B G protein-coupled receptor expressed predominantly on anterior pituitary somatotrophs. Ligand binding activates Gαs-mediated adenylyl cyclase signaling, increasing intracellular cAMP and activating protein kinase A (PKA). PKA phosphorylation cascades regulate GH gene transcription via CREB and Pit-1 transcription factors, and trigger secretory granule exocytosis. GHRHR also signals through phospholipase C in some contexts, generating IP3 and mobilizing intracellular calcium. Research compound — not for human use.

Mayo KE et al. “Growth hormone-releasing hormone: synthesis and signaling.” Recent Prog Horm Res. 2000. PubMed

GHRH Analogs and Somatotroph Proliferation

In addition to stimulating acute GH release, GHRH receptor activation promotes somatotroph proliferation and differentiation through cAMP-dependent and Wnt/β-catenin signaling pathways. Studies in GHRH-knockout mouse models demonstrate that absence of endogenous GHRH results in severe pituitary hypoplasia and dwarfism, while exogenous GHRH analog administration partially restores somatotroph populations and somatic growth. These models characterize the trophic role of GHRH signaling in pituitary development. Research compound — not for human use.

Alba M, Bhangoo A, Bhatt S, Bhatt R. “The GH axis in the GHRH KO mouse.” Rev Endocr Metab Disord. 2005. PubMed

Disclaimer: All research citations are provided for educational purposes only. These references describe findings from in vitro and animal model studies. This information does not constitute medical advice and should not be interpreted as endorsement of any specific application.

Reviewed by

Dr. James Porter, PhD

Biochemist with a focus on peptide synthesis and structure-activity relationships. Reviews research summaries for scientific accuracy.

Editorial Review

Reviewed by Dr. Sarah Chen, PharmD and Dr. James Porter, PhD — Panda Peptides Research Team.

Last reviewed: April 2026.

This content summarizes published peer-reviewed research for educational purposes only. It is not medical advice and does not constitute a recommendation for any specific compound or protocol.